{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001529","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2023-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.326073+00:00","generated_at":"2026-06-09T15:47:47.115229+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"USANA Q3 net sales $213M, EPS $0.59; narrows FY 2023 guidance","bullets":["Q3 net sales $213M (-9% YoY); diluted EPS $0.59 (-24% YoY).","Active customers 464,000 (-2% YoY); Asia Pacific region sales $170M (-7% YoY).","Greater China net sales $107M (-3% YoY, +2% constant currency); active customers +8%.","FY 2023 outlook narrowed: net sales $900-$920M, EPS $2.80-$3.05 (prev. $900-$950M, $2.65-$3.30).","Repurchased 180K shares for $12M; ended quarter debt-free with $307M cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001529","json":"https://secwatch.observer/filing/0001157523-23-001529.json","markdown":"https://secwatch.observer/filing/0001157523-23-001529.md","text":"https://secwatch.observer/filing/0001157523-23-001529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752323001529/0001157523-23-001529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752323001529/a53675959.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T15:47:47.115229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d93190ee4052ca6e6fac2401e7ab171167b532df","claim":"USANA HEALTH SCIENCES INC reported the third quarter ended September 30, 2023 results: revenue $213 million, EPS $0.59.","evidence_excerpt":"Third quarter net sales were $213 million versus $233 million during Q3 2022. Third quarter diluted EPS was $0.59 as compared with $0.78 during Q3 2022. Company narrows fiscal year 2023 net sales and diluted EPS outlook to $900 million to $920 million and $2.80 to $3.05, respectively (previously $900 million to $950 million and $2.65 to $3.30).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896264/000115752323001529/0001157523-23-001529-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$213 million"},{"label":"EPS","value":"$0.59"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}